Literature DB >> 218985

Immunoreactive somatomedin A in human serum.

K Hall, J Brandt, G Enberg, L Fryklund.   

Abstract

A RIA has been developed for somatomedin A (SM-A) utilizing Sepharose-bound antibodies. This assay, measuring SM-A, the insulin-like growth factors 1 and 2, and somatomedin C, allows determination in serum samples. In comparison with a serum standard, the mean serum levels in patients with acromegaly or GH deficiency and healthy subjects were 8.7 %/- 0.7 (n = 25), 0.24 +/- 0.02 (n = 25), and 1.15 +/- 0.11 U/ml, respectively. The correlation coefficient between immunoreactive SM-A and SM-A by radioreceptor assay was highly significant (r = 0.93), although the potency ratio of SM-A between the two groups of patients was higher in the RIA than in the radioreceptor assay. Gel chromatography revealed that SM-A in acromegalic serum is bound to a carrier protein which is absent in patients with GH deficiency. After gel chromatography at low pH, 90% of applied immunoreactive SM-A was recovered in the low molecular weight fraction and consisted mainly of neutral polypeptides.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 218985     DOI: 10.1210/jcem-48-2-271

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  15 in total

Review 1.  Somatomedins: chemical and functional characteristics of the different molecular forms.

Authors:  A Barreca; F Minuto
Journal:  J Endocrinol Invest       Date:  1989-04       Impact factor: 4.256

2.  Insulin regulates the 35 kDa IGF binding protein in patients with diabetes mellitus.

Authors:  K Brismar; M Gutniak; G Povoa; S Werner; K Hall
Journal:  J Endocrinol Invest       Date:  1988-09       Impact factor: 4.256

Review 3.  Physical activity in the prevention and amelioration of osteoporosis in women : interaction of mechanical, hormonal and dietary factors.

Authors:  Katarina T Borer
Journal:  Sports Med       Date:  2005       Impact factor: 11.136

4.  Growth hormone secretion in empty sella syndrome.

Authors:  K Brismar
Journal:  J Endocrinol Invest       Date:  1982 Nov-Dec       Impact factor: 4.256

5.  Circulating insulin-like growth factor I in type 1 (insulin-dependent) diabetic patients with retinopathy.

Authors:  P Arner; S Sjöberg; M Gjötterberg; A Skottner
Journal:  Diabetologia       Date:  1989-10       Impact factor: 10.122

6.  Preferential association of the insulin-like growth factors I and II with metabolically inactive and active carrier-bound complexes in serum.

Authors:  H J Cornell; G Enberg; A C Herington
Journal:  Biochem J       Date:  1987-02-01       Impact factor: 3.857

7.  Growth and somatomedin responses to growth hormone in Down's syndrome.

Authors:  G Annerén; V R Sara; K Hall; T Tuvemo
Journal:  Arch Dis Child       Date:  1986-01       Impact factor: 3.791

8.  Characterization of somatomedins from human fetal brain: identification of a variant form of insulin-like growth factor I.

Authors:  V R Sara; C Carlsson-Skwirut; C Andersson; E Hall; B Sjögren; A Holmgren; H Jörnvall
Journal:  Proc Natl Acad Sci U S A       Date:  1986-07       Impact factor: 11.205

9.  Human embryonic somatomedin.

Authors:  V R Sara; K Hall; C H Rodeck; L Wetterberg
Journal:  Proc Natl Acad Sci U S A       Date:  1981-05       Impact factor: 11.205

10.  Radioimmunological determination of insulinlike growth factors I and II in normal subjects and in patients with growth disorders and extrapancreatic tumor hypoglycemia.

Authors:  J Zapf; H Walter; E R Froesch
Journal:  J Clin Invest       Date:  1981-11       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.